.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Deloitte
Queensland Health
US Department of Justice
Fish and Richardson
Healthtrust
Federal Trade Commission
Express Scripts
Medtronic

Generated: December 14, 2017

DrugPatentWatch Database Preview

Egalet Us Inc Company Profile

« Back to Dashboard

What is the competitive landscape for EGALET US INC, and when can generic versions of EGALET US INC drugs launch?

EGALET US INC has two approved drugs.

There are seven US patents protecting EGALET US INC drugs.

There are twenty-two patent family members on EGALET US INC drugs in twelve countries and seven supplementary protection certificates in six countries.

Summary for Egalet Us Inc

International Patents:22
US Patents:7
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-002Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
Egalet Us IncOXAYDOoxycodone hydrochlorideTABLET;ORAL202080-001Jun 17, 2011RXNoNo► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Egalet Us Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Egalet Us IncSPRIXketorolac tromethamineSPRAY, METERED;NASAL022382-001May 14, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for EGALET US INC drugs

Drugname Dosage Strength Tradename Submissiondate
ketorolac tromethamineNasal Spray15.75 mg/spraySPRIX3/12/2012

Non-Orange Book Patents for Egalet Us Inc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,267,827Therapeutic compositions for intranasal administration which include KETOROLAC► Subscribe
8,101,630Extended release opioid abuse deterrent compositions and methods of making same► Subscribe
8,822,489Abuse deterrent compositions and methods of making same► Subscribe
7,476,402Methods and compositions for deterring abuse of opioid containing dosage forms► Subscribe
7,476,689Therapeutic compositions for intranasal administration which include KETOROLAC► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Egalet Us Inc Drugs

Country Document Number Estimated Expiration
Japan3586735► Subscribe
Australia2013206525► Subscribe
JapanH05194215► Subscribe
World Intellectual Property Organization (WIPO)2005053587► Subscribe
Australia2015264950► Subscribe
Denmark0524587► Subscribe
Israel175863► Subscribe
Greece3019012► Subscribe
Canada2547334► Subscribe
Australia2010200979► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Egalet Us Inc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
923Luxembourg► SubscribePRODUCT NAME: UNE SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION: 20150730
C0090France► SubscribePRODUCT NAME: SOLUTION D'IRRIGATION OCULAIRE COMPRENANT DE LA PHENYLEPHRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI ET DU KETOROLAC OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1018 20150728
/2015Austria► SubscribePRODUCT NAME: PHENYLEPHRIN, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, UND KETOROLAC, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1018 (MITTEILUNG) 20150730
0784Netherlands► SubscribePRODUCT NAME: EEN OCULAIRE OPLOSSING WELKE FENYLEFRINE BEVAT, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN, ALSMEDE KETOROLAC, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/15/1018 20150730
2015000111Germany► SubscribePRODUCT NAME: OKULARE IRRIGATIONSLOESUNG, WELCHE PHENYLEPHRIN ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UND KETOROLAC ODER DESSEN PHARMAZEUTISCH WIRKSAMES SALZ UMFASST; REGISTRATION NO/DATE: EU/1/15/1018 20150728
2015 00072Denmark► SubscribePRODUCT NAME: OKULAER SKYLLEVAESKE OMFATTENDE PHENYLEPHRIN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER HYDROCHLORID OG KETOROLAC ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER KETOROLACTROMETAMOL; REG. NO/DATE: EU/1/15/1018 20150730
292Luxembourg► SubscribePRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
Baxter
Julphar
Queensland Health
McKesson
Cantor Fitzgerald
Colorcon
Medtronic
Argus Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot